期刊
DRUG DISCOVERY TODAY
卷 18, 期 3-4, 页码 116-127出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2012.09.003
关键词
-
资金
- National Institutes of Health [R01 GM088244]
- Cystic Fibrosis Research Foundation [1060]
A crucial question that must be addressed in the drug development process is whether the proposed therapeutic target will yield the desired effect in the clinical population. Pharmaceutical and biotechnology companies place a large investment on research and development, long before confirmatory data are available from human trials. Basic science has greatly expanded the computable knowledge of disease processes, both through the generation of large omics data sets and a compendium of studies assessing cellular and systemic responses to physiologic and pathophysiologic stimuli. Given inherent uncertainties in drug development, mechanistic systems models can better inform target selection and the decision process for advancing compounds through preclinical and clinical research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据